Linifanib

Drug Profile

Linifanib

Alternative Names: A-741439; ABT-869; RG-3635

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie
  • Class Antineoplastics; Indazoles; Phenylurea compounds; Small molecules; Urea compounds
  • Mechanism of Action Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Hepatocellular carcinoma; Non-small cell lung cancer; Renal cancer

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 01 Sep 2012 Abbott terminates phase I trial in Solid tumours in USA (NCT01286974)
  • 24 Aug 2012 Abbott terminates a phase I trial in Solid tumours in US (NCT01506934)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top